These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20467169)

  • 21. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".
    Simon JA
    Arch Intern Med; 2011 Apr; 171(8):777-8. PubMed ID: 21518947
    [No Abstract]   [Full Text] [Related]  

  • 23. [Varenicline - pharmacological therapy of tobacco dependence].
    Tschabitscher P; Homaier I; Lichtenschopf A; Groman E
    Wien Med Wochenschr; 2009; 159(1-2):17-23. PubMed ID: 19225731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Varenicline reduced smoking behaviour in a mentally ill person.
    Ochoa EL
    J Psychopharmacol; 2009 May; 23(3):340-1. PubMed ID: 18562426
    [No Abstract]   [Full Text] [Related]  

  • 25. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The most addictive drug, the most deadly substance: smoking cessation tactics for the busy clinician.
    Crane R
    Prim Care; 2007 Mar; 34(1):117-35. PubMed ID: 17481990
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
    Foulds J
    Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Varenicline for tobacco dependence.
    Cantrell MA; Geraets D
    N Engl J Med; 2009 Feb; 360(7):730-1. PubMed ID: 19213691
    [No Abstract]   [Full Text] [Related]  

  • 31. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
    Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
    Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Varenicline for smoking cessation: definite promise, but no panacea.
    Klesges RC; Johnson KC; Somes G
    JAMA; 2006 Jul; 296(1):94-5. PubMed ID: 16820552
    [No Abstract]   [Full Text] [Related]  

  • 33. Varenicline as maintenance therapy.
    O'Brien CP
    Curr Psychiatry Rep; 2007 Oct; 9(5):347-8. PubMed ID: 17915072
    [No Abstract]   [Full Text] [Related]  

  • 34. Varenicline for smokeless tobacco dependence.
    Aggarwal A; Jain M; Jiloha RC
    J Postgrad Med; 2010; 56(1):50. PubMed ID: 20393259
    [No Abstract]   [Full Text] [Related]  

  • 35. Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?
    Nocente R; Vitali M; Balducci G; Enea D; Kranzler HR; Ceccanti M
    Am J Addict; 2013; 22(5):453-9. PubMed ID: 23952890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating smoking cessation into HIV care.
    Drach L; Holbert T; Maher J; Fox V; Schubert S; Saddler LC
    AIDS Patient Care STDS; 2010 Mar; 24(3):139-40. PubMed ID: 20214480
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of nicotine dependence with Chantix (varenicline).
    Rankin KV; Jones DL
    Tex Dent J; 2011 May; 128(5):457-61. PubMed ID: 21834368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.
    Chatterjee S; Bartlett SE
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):60-76. PubMed ID: 20201817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
    Rollema H; Russ C; Lee TC; Hurst RS; Bertrand D
    Nicotine Tob Res; 2014 Jun; 16(6):733-42. PubMed ID: 24406270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.